347 related articles for article (PubMed ID: 19795182)
21. CGRP receptors in the control of pain and inflammation.
Benemei S; Nicoletti P; Capone JG; Geppetti P
Curr Opin Pharmacol; 2009 Feb; 9(1):9-14. PubMed ID: 19157980
[TBL] [Abstract][Full Text] [Related]
22. CGRP - a target for acute therapy in migraine: Clinical data.
Messina R; Goadsby PJ
Cephalalgia; 2019 Mar; 39(3):420-427. PubMed ID: 29616830
[TBL] [Abstract][Full Text] [Related]
23. Randomized, controlled trial of telcagepant for the acute treatment of migraine.
Connor KM; Shapiro RE; Diener HC; Lucas S; Kost J; Fan X; Fei K; Assaid C; Lines C; Ho TW
Neurology; 2009 Sep; 73(12):970-7. PubMed ID: 19770473
[TBL] [Abstract][Full Text] [Related]
24. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
[TBL] [Abstract][Full Text] [Related]
25. Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
[TBL] [Abstract][Full Text] [Related]
26. Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment.
Tfelt-Hansen P
J Headache Pain; 2011 Jun; 12(3):275-80. PubMed ID: 21350792
[TBL] [Abstract][Full Text] [Related]
27. CGRP antagonists: unravelling the role of CGRP in migraine.
Doods H; Arndt K; Rudolf K; Just S
Trends Pharmacol Sci; 2007 Nov; 28(11):580-7. PubMed ID: 17963849
[TBL] [Abstract][Full Text] [Related]
28. The tortuous road to an ideal CGRP function blocker for the treatment of migraine.
Davis CD; Xu C
Curr Top Med Chem; 2008; 8(16):1468-79. PubMed ID: 18991732
[TBL] [Abstract][Full Text] [Related]
29. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.
Ho TW; Ho AP; Chaitman BR; Johnson C; Mathew NT; Kost J; Fan X; Aurora SK; Brandes JL; Fei K; Beebe L; Lines C; Krucoff MW
Headache; 2012 Feb; 52(2):224-35. PubMed ID: 22221076
[TBL] [Abstract][Full Text] [Related]
30. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Mitsikostas DD; Tfelt-Hansen P
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751
[TBL] [Abstract][Full Text] [Related]
31. The Journey of the Non-Vascular Relief for Migraine: From 'Triptans' To 'Ditans'.
Xavier AS; Lakshmanan M; Gunaseelan V
Curr Clin Pharmacol; 2017; 12(1):36-40. PubMed ID: 28425871
[TBL] [Abstract][Full Text] [Related]
32. ACS chemical neuroscience molecule spotlight on Telcagepant (MK-0974).
Hopkins CR
ACS Chem Neurosci; 2011 Jul; 2(7):334-5. PubMed ID: 22816019
[TBL] [Abstract][Full Text] [Related]
33. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.
Hougaard A; Tfelt-Hansen P
Expert Opin Drug Metab Toxicol; 2015; 11(9):1409-18. PubMed ID: 26095133
[TBL] [Abstract][Full Text] [Related]
34. [CGRP antagonists: novel concept for treatment of migraine].
Nieber K
Med Monatsschr Pharm; 2009 May; 32(5):182-5. PubMed ID: 19469188
[TBL] [Abstract][Full Text] [Related]
35. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine.
Moore EL; Burgey CS; Paone DV; Shaw AW; Tang YS; Kane SA; Salvatore CA
Eur J Pharmacol; 2009 Jan; 602(2-3):250-4. PubMed ID: 19084002
[TBL] [Abstract][Full Text] [Related]
36. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.
Tfelt-Hansen P
Headache; 2011 Jan; 51(1):118-23. PubMed ID: 21070229
[TBL] [Abstract][Full Text] [Related]
37. Calcitonin gene-related peptide receptor antagonists for migraine.
Fischer MJ
Expert Opin Investig Drugs; 2010 Jul; 19(7):815-23. PubMed ID: 20482328
[TBL] [Abstract][Full Text] [Related]
38. Management of acute and chronic migraine.
Coppola G; Schoenen J
Curr Opin Support Palliat Care; 2012 Jun; 6(2):177-82. PubMed ID: 22406987
[TBL] [Abstract][Full Text] [Related]
39. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
Gupta S; Villalón CM
Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
[TBL] [Abstract][Full Text] [Related]
40. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors.
Tajti J; Csáti A; Vécsei L
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1509-20. PubMed ID: 25253587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
